In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Adverse Event Reporting in Clinical Trials A pharmacovigilance datadriven approach to reveal high fatal adverse events following checkpoint immunotherapy PNAS Documenting Adverse Events Applied Clinical Trials Online